ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 168 filers reported holding ASCENDIS PHARMA A/S in Q1 2023. The put-call ratio across all filers is 0.19 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $253,420 | -4.7% | 2,075 | -19.4% | 0.17% | -5.5% |
| Q3 2022 | $266,000 | +8.1% | 2,575 | -2.7% | 0.18% | +4.6% |
| Q2 2022 | $246,000 | -20.6% | 2,646 | +0.1% | 0.18% | -11.2% |
| Q1 2022 | $310,000 | -21.5% | 2,644 | -9.9% | 0.20% | -18.6% |
| Q4 2021 | $395,000 | +4.5% | 2,936 | +23.8% | 0.24% | -2.4% |
| Q3 2021 | $378,000 | +17.0% | 2,371 | -3.4% | 0.25% | +24.6% |
| Q2 2021 | $323,000 | -1.5% | 2,455 | -3.6% | 0.20% | -6.1% |
| Q1 2021 | $328,000 | -21.2% | 2,547 | +2.0% | 0.21% | -25.4% |
| Q4 2020 | $416,000 | +16.9% | 2,497 | +8.3% | 0.28% | -1.0% |
| Q3 2020 | $356,000 | +17.5% | 2,305 | +12.6% | 0.29% | +14.3% |
| Q2 2020 | $303,000 | – | 2,047 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |